1. A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma. (March 2018) Authors: Cohen, Steven J.; Zalupski, Mark M.; Conkling, Paul; Nugent, Francis; Ma, Wen Wee; Modiano, Manuel; Pascual, Rolan; Lee, Fa Chyi; Wong, Lucas; Hersh, Evan Journal: American journal of clinical oncology Issue: Volume 41:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma. (31st December 2018) Authors: El Dika, Imane; Lim, Ho Yeong; Yong, Wei Peng; Lin, Chia‐Chi; Yoon, Jung‐Hwan; Modiano, Manuel; Freilich, Bradley; Choi, Hye Jin; Chao, Tsu‐Yi; Kelley, Robin K.; Brown, Joanne; Knox, Jennifer; Ryoo, Baek‐Yeol; Yau, Thomas; Abou‐Alfa, Ghassan K. Journal: Oncologist Issue: Volume 24:Number 6(2019) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗